Abstract No.LBA7502Indication: Non-small cell lung cancer Clinical Trial: Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-negative patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Presentation Time: Saturday, June 5. Oral session. Notes: Arqule announced top-line results from this phase II study of ARQ 197 at the end of March. ASCO did not release the research abstract for ARQ 197 Thursday night.